Here's an educated guess by EvaluatePharma via The Pharmalot blog as to which drugs will be the top sellers in 2018 as well as the overall ranking of companies by total sales that same year.
On the drug side, Januvia ($9.7 B in 2018) is expected to pull ahead of this year's new leader Humira ($8.2 B in 2018). Humira will still be number two, followed by Avastin ($7.5 B), Enbrel ($7.2 B) and Revlimid ($6.75 B). See link for rest of top 10. Januvia, Revlimid and Prevnar are all expected to grow more than 9% CAGR between now and 2018.
On the company side of things, Novartis ($51.3 B) is expected to take over the number 1 position from Pfizer ($48.2 B) and Sanofi ($48.2 B). Novartis' 5.8% market share will also top the field. Eli Lilly is expected to be the biggest loser taking a ride on the lead balloon to sink to $13.7 B, dropping 6% in sales and holding then 1.6% share.
That's what the prognosticators predict. Happy Flag Day!
Posted by Bruce Lehr June 14th 2012.